Please assess the completion status of the following clinical trial:

Trial Title: Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients~* Aged 18 or older~* Non-HLA identical with the donor (one or two haplotype mismatches)~* First kidney transplant~* Capable of understanding the purpose and risk of the study~* Written informed consent~Exclusion Criteria:~* MSC donor positive for HIV-1, HIV-2, HBV, HCV, Syphilis.~* Specific contraindication to MSC infusion~* Any clinical relevant condition that might affect study participation and/or study results~* Pregnant women and nursing mothers~* Unwillingness or inability to follow study protocol in the investigator's opinion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).